Form 144: Proposed AXSM Common Stock Sales

Charles Schwab & Co., Inc. submitted a Form 144 reporting proposed sales of Common stock of Axsome Therapeutics, Inc. under an Equity Compensation event tied to a Restricted Stock Lapse dated 06/06/2026.

Rhea-AI Filing Summary

Charles Schwab & Co., Inc. submitted a Form 144 reporting proposed sales of Common stock of Axsome Therapeutics, Inc. under an Equity Compensation event tied to a Restricted Stock Lapse dated 06/06/2026. The filing lists recent sales by Mark Coleman: 6,000 shares on 05/29/2026, 6,000 shares on 06/01/2026, and 5,537 shares on 06/02/2026.

Key Figures

Restricted Stock Lapse date: 06/06/2026 Sale - 05/29/2026: 6,000 shares Sale - 06/01/2026: 6,000 shares +1 more

4 metrics

Restricted Stock Lapse date 06/06/2026 Securities to be sold listed as 'Restricted Stock Lapse'

Sale - 05/29/2026 6,000 shares Mark Coleman reported sale on 05/29/2026

Sale - 06/01/2026 6,000 shares Mark Coleman reported sale on 06/01/2026

Sale - 06/02/2026 5,537 shares Mark Coleman reported sale on 06/02/2026

Key Terms

Rule 144 / Form 144, Restricted Stock Lapse, Equity Compensation

3 terms

Rule 144 / Form 144 regulatory

"144: Securities To Be Sold"

Restricted Stock Lapse financial

"Securities To Be Sold | Restricted Stock Lapse | 06/06/2026"

Equity Compensation financial

"Securities To Be Sold | Equity Compensation"

Equity compensation is pay given to employees, executives or contractors in the form of company ownership—such as stock, stock options or restricted shares—rather than just cash. It matters to investors because it can align workers' incentives with shareholders (like paying someone in slices of the same pie they help grow), but it also increases the number of shares outstanding and company expenses, affecting ownership percentages and earnings per share.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What does the Form 144 for AXSM report?

The Form 144 reports proposed sales of Common stock of Axsome Therapeutics related to an Equity Compensation event. It references a Restricted Stock Lapse dated 06/06/2026 and lists recent sales by Mark Coleman totaling specific share amounts on given dates.

How many AXSM shares are shown sold in the filing's recent transactions?

The filing shows three recent transactions by Mark Coleman: 6,000 shares on 05/29/2026, 6,000 shares on 06/01/2026, and 5,537 shares on 06/02/2026. Each entry includes a dollar value per the report.

Who is the filer and which broker is listed on the AXSM Form 144?

The filing lists Charles Schwab & Co., Inc. as the broker/filing intermediary. The issuer named is Axsome Therapeutics, Inc. and the reported transactions reference the individual Mark Coleman at the provided address.

What event triggered the securities to be eligible for sale in this AXSM filing?

The excerpt states the securities to be sold are tied to a Restricted Stock Lapse dated 06/06/2026, categorized under Equity Compensation, indicating vesting or lapse of restrictions made the shares eligible for resale.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 04:15 PM EDT Learn about SEC filing dates

Form 144 Filer Information	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 144 NOTICE OF PROPOSED SALE OF SECURITIES PURSUANT TO RULE 144 UNDER THE SECURITIES ACT OF 1933
FORM 144

144: Filer Information

Filer CIK	0001658379
Filer CCC	XXXXXXXX
Is this a LIVE or TEST Filing?	LIVE TEST
Submission Contact Information
Name
Phone
E-Mail Address

144: Issuer Information

Name of Issuer	Axsome Therapeutics, Inc.
SEC File Number	001-37635
Address of Issuer	ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NEW YORK 10007
Phone	(212) 332-3241
Name of Person for Whose Account the Securities are To Be Sold	Coleman Mark
See the definition of "person" in paragraph (a) of Rule 144. Information is to be given not only as to the person for whose account the securities are to be sold but also as to all other persons included in that definition. In addition, information shall be given as to sales by all persons whose sales are required by paragraph (e) of Rule 144 to be aggregated with sales for the account of the person filing this notice.
Relationship to Issuer	Director

144: Securities Information

Title of the Class of Securities To Be Sold	Name and Address of the Broker	Number of Shares or Other Units To Be Sold	Aggregate Market Value	Number of Shares or Other Units Outstanding	Approximate Date of Sale	Name the Securities Exchange
Common	Charles Schwab & Co., Inc. 3000 Schwab Way Westlake TX 76262	643	160109.00	51459766	06/10/2026	NASDAQ

Furnish the following information with respect to the acquisition of the securities to be sold and with respect to the payment of all or any part of the purchase price or other consideration therefor:

144: Securities To Be Sold

Title of the Class	Date you Acquired	Nature of Acquisition Transaction	Name of Person from Whom Acquired	Is this a Gift?	Date Donor Acquired	Amount of Securities Acquired	Date of Payment	Nature of Payment *
Common	06/06/2026	Restricted Stock Lapse	Axsome Therapeutics, Inc.			643	06/06/2026	Equity Compensation

* If the securities were purchased and full payment therefor was not made in cash at the time of purchase, explain in the table or in a note thereto the nature of the consideration given. If the consideration consisted of any note or other obligation, or if payment was made in installments describe the arrangement and state when the note or other obligation was discharged in full or the last installment paid.

Furnish the following information as to all securities of the issuer sold during the past 3 months by the person for whose account the securities are to be sold.

144: Securities Sold During The Past 3 Months

Name and Address of Seller	Title of Securities Sold	Date of Sale	Amount of Securities Sold	Gross Proceeds
MARK COLEMAN ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	05/29/2026	6000	1400783.00
MARK COLEMAN ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	06/01/2026	6000	1381798.00
MARK COLEMAN ONE WORLD TRADE CENTER, 29TH FLOOR NEW YORK NY 10007	Axsome Therapeutics, Inc.	06/02/2026	5537	1236885.00

144: Remarks and Signature

Remarks
Date of Notice	06/10/2026
Date of Plan Adoption or Giving of Instruction, If Relying on Rule 10b5-1	02/27/2026
ATTENTION:
The person for whose account the securities to which this notice relates are to be sold hereby represents by signing this notice that he does not know any material adverse information in regard to the current and prospective operations of the Issuer of the securities to be sold which has not been publicly disclosed. If such person has adopted a written trading plan or given trading instructions to satisfy Rule 10b5-1 under the Exchange Act, by signing the form and indicating the date that the plan was adopted or the instruction given, that person makes such representation as of the plan adoption or instruction date.
Signature	MARK COLEMAN
ATTENTION: Intentional misstatements or omission of facts constitute Federal Criminal Violations (See 18 U.S.C. 1001)